FDA
-
-
-
-
-
-
-
TG Therapeutics Announces Publication of Post-Hoc Data from the Phase 3 ULTIMATE I & II Trials in Treatment Naive Patients with Relapsing Forms of MS Published in Frontiers in Immunology
-
-
-
-
-
-
-
Precision BioSciences Reports First Quarter 2026 Financial Results and Provides Business Update
-
-
-
-
-
-
-
TG Therapeutics Secures an Additional $500 Million in Non-Dilutive Capital from Blue Owl and Expands Share Repurchase Program to $300 Million
-
-
-
-
-
-
-
TG Therapeutics to Host Conference Call on Fourth Quarter and Full Year 2025 Financial Results and Business Update
-
-
-
-
-
-
-
TG Therapeutics reports $616M 2025 revenue, targets $875-900M for 2026
-
-
-
-
-
-
-
TG Therapeutics to Host Conference Call on Third Quarter 2025 Financial Results and Business Update
-
-
-
-
-
-
-
TG Announces Phase 3 Trial for Subcutaneous BRIUMVI Commenced Enrollment
-
323,573 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

